EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, IDEAYA Biosciences's enterprise value is €947.62 Mil.
IDEAYA Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was €-332.71 Mil. Therefore, IDEAYA Biosciences's EV-to-EBITDA for today is -2.85.
The historical rank and industry rank for IDEAYA Biosciences's EV-to-EBITDA or its related term are showing as below:
FRA:30J'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.72 Med: -8.36 Max: -1.47
Current: -3.02
During the past 8 years, the highest EV-to-EBITDA of IDEAYA Biosciences was -1.47. The lowest was -21.72. And the median was -8.36.
FRA:30J's EV-to-EBITDA is ranked worse than 100% of 493
companies
in the Biotechnology industry
Industry Median: 8.65
vs FRA:30J: -3.02
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
IDEAYA Biosciences EV-to-EBITDA Historical Data
The historical data trend for IDEAYA Biosciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of IDEAYA Biosciences's EV-to-EBITDA
For the Biotechnology subindustry, IDEAYA Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEAYA Biosciences's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where IDEAYA Biosciences's EV-to-EBITDA falls into.
IDEAYA Biosciences's current Enterprise Value is €947.62 Mil.
IDEAYA Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-332.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
IDEAYA Biosciences's PE Ratio (TTM) for today is calculated as:
IDEAYA Biosciences's share price for today is €17.60.
IDEAYA Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.354.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of IDEAYA Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:30J has been successfully added to your 